Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic Acid (OCA) in Familial Adenomatous Polyposis (FAP)
NCT05223036Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jan 2023
- Primary completion
- Mar 2026
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in familial adenomatous polyposis (FAP) comparing Arm I (OCA) with Arm II (placebo) (2 arms). Primary endpoint: Percentage change in duodenal polyp burden at 6 months. Started Jan 2023; status: terminated.
02
Drugs
obeticholic acid
03
Conditions
familial adenomatous polyposis (FAP)
Beyond the preview
Go deeper on NCT05223036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05223036.